Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma
AffiliationManchester Centre of Health Psychology, Division of Psychology & Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchester
MetadataShow full item record
Abstract"Background: Circulating tumour DNA (ctDNA) monitoring is a new technology that detects cancer DNA fragments in blood circulation. Regular monitoring with ctDNA has the potential to detect and treat cancer relapse earlier, but there is little evidence on patient acceptability. This study examines the views of patients with early-stage melanoma on the acceptability of the test and early treatment. Methods: A qualitative cross-sectional design using one-to-one semi-structured telephone interviews was employed. Twenty-five patients diagnosed with early-stage melanoma (Stage IA-IIC) were asked for their views on ctDNA monitoring and early treatment for relapse. Interviews were analysed using reflexive thematic analysis. Results: Two themes were generated: ctDNA monitoring would add service value where participants described regular ctDNA monitoring in follow-up care as more reassuring, more ""scientific"" than skin checks and preferable to scans. Test results provide opportunity and knowledge focuses on how participants wanted to know when to expect results to manage anxiety, with a positive result seen as an opportunity to receive treatment early. Conclusions: Participants were positive about ctDNA monitoring and early treatment and would welcome extra surveillance, as well as trust ctDNA tests. This indicates the feasibility of the wider implementation of ctDNA tests, which have applicability for many tumour types and disease stages."
CitationWoof, V. G, Lee, R J, Lorigan, P C, French, D P
JournalBritish Journal of Cancer
- Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
- Authors: Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ
- Issue date: 2019 May 1
- Circulating Tumour DNA in Melanoma-Clinic Ready?
- Authors: Tivey A, Britton F, Scott JA, Rothwell D, Lorigan P, Lee R
- Issue date: 2022 Mar
- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
- Authors: Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, Rundell V, Wulff J, Sharma G, Knock H, Castedo J, Cooper W, Zhao H, Smith CG, Garg S, Anand S, Howarth K, Gilligan D, Harden SV, Rassl DM, Rintoul RC, Rosenfeld N
- Issue date: 2022 May
- Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up.
- Authors: Relton A, Collins A, Guttery DS, Gorsia DN, McDermott HJ, Moss EL
- Issue date: 2021 Jul
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
- Authors: Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H
- Issue date: 2019 May 1